Fenoglide is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Santarus, Inc.. The primary component is Fenofibrate.
Product ID | 68012-495_111abed0-61c5-49ad-b381-d3a20540cd19 |
NDC | 68012-495 |
Product Type | Human Prescription Drug |
Proprietary Name | Fenoglide |
Generic Name | Fenofibrate |
Dosage Form | Tablet |
Route of Administration | ORAL |
Marketing Start Date | 2010-11-18 |
Marketing Category | NDA / NDA |
Application Number | NDA022118 |
Labeler Name | Santarus, Inc. |
Substance Name | FENOFIBRATE |
Active Ingredient Strength | 120 mg/1 |
Pharm Classes | Peroxisome Proliferator Receptor alpha Agonist [EPC] |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2010-11-18 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA022118 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2010-11-18 |
Marketing Category | NDA |
Application Number | NDA022118 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2010-11-18 |
Ingredient | Strength |
---|---|
FENOFIBRATE | 120 mg/1 |
SPL SET ID: | 35e89d4e-45cf-4374-bf93-fca8d40d783b |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
68012-490 | Fenoglide | Fenoglide |
68012-495 | Fenoglide | Fenoglide |
52725-490 | Fenoglide | Fenoglide |
52725-495 | Fenoglide | Fenoglide |
0093-7755 | Fenofibrate | Fenofibrate |
0093-7756 | Fenofibrate | Fenofibrate |
0115-0511 | Fenofibrate | FENOFIBRATE |
0115-0522 | Fenofibrate | FENOFIBRATE |
0115-0533 | Fenofibrate | FENOFIBRATE |
0115-1522 | Fenofibrate | Fenofibrate |
0115-1523 | Fenofibrate | Fenofibrate |
0115-5511 | FENOFIBRATE | FENOFIBRATE |
0115-5522 | FENOFIBRATE | FENOFIBRATE |
0074-3173 | Tricor | Fenofibrate |
0074-3189 | Tricor | Fenofibrate |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
FENOGLIDE 77381746 3528941 Live/Registered |
SANTARUS, INC. 2008-01-28 |